The short answer
AML is not staged like a solid tumor. Instead, doctors sort it into favorable, intermediate, or adverse risk groups based on chromosome changes (cytogenetics) and gene mutations found in the leukemia cells, which helps guide how intensive treatment should be.
AML does not have a stage I to IV. Instead, it is risk-stratified using chromosome changes (cytogenetics) and specific gene mutations found in the leukemia cells.
Risk groups are broadly described as favorable, intermediate, and adverse (also called unfavorable or poor-risk), based on frameworks such as the European LeukemiaNet (ELN) classification used by hematologists.
Favorable changes include a translocation between chromosomes 8 and 21, an inversion or translocation of chromosome 16, and mutations in the NPM1 or CEBPA genes (without an FLT3 mutation also present).
Adverse changes include loss of part of chromosome 5 or 7, complex chromosome changes involving three or more chromosomes, and mutations in genes such as FLT3, TP53, RUNX1, and ASXL1.
Choose how you want to understand this
The full explanation.
The simple version
AML is not staged the way breast, lung, or colon cancer is staged. There is no stage I through IV. Instead, hematologists — doctors who specialize in blood cancers — sort AML into risk groups based on the chromosome changes (cytogenetics) and gene mutations found in the leukemia cells. These groups are broadly described as favorable, intermediate, and adverse (sometimes called unfavorable or poor-risk) risk.
AML risk grouping is genetic, not geographic. It is not about how far the cancer has spread; it is about which chromosome and gene changes the leukemia cells carry.
Why genetics instead of a stage
A cancer stage usually answers "how big is it, and how far has it spread?" AML is already present throughout the blood and bone marrow at diagnosis, so that kind of question doesn't map well onto it. What predicts outcome instead is the biology of the leukemia cells themselves — specific chromosome rearrangements and gene mutations that research has linked, again and again, to how well AML responds to treatment.
This is arguably more useful than a spread-based stage: two people with the same "amount" of leukemia in the marrow can have very different outlooks depending on genetics, and genetics also point directly to specific targeted treatments in some cases.
What goes into the risk group
Your pathology report will list results from cytogenetic testing (chromosome analysis) and molecular testing (gene mutation analysis). Some of the changes linked to a more favorable course include:
- A translocation (an exchange of material) between chromosomes 8 and 21
- An inversion or translocation involving chromosome 16
- A mutation in the NPM1 gene, when a FLT3 mutation is not also present
- A mutation in the CEBPA gene
Some of the changes linked to a less favorable, adverse course include:
- Loss of part of chromosome 5 or chromosome 7
- Complex chromosome changes, meaning three or more chromosome abnormalities together
- A mutation in the FLT3 gene (though targeted therapies exist for this)
- Mutations in TP53, RUNX1, or ASXL1
People whose AML cells have none of these specific favorable or adverse changes generally fall into an intermediate group, with an outlook between the two.
This favorable/intermediate/adverse framework is formalized in expert guidelines such as those published by the European LeukemiaNet (ELN), an international group of leukemia specialists, and is widely used by hematology teams to help guide treatment intensity.
What risk group changes about treatment
Risk group is one input, not the only one, into decisions about how intensive treatment should be and whether a stem cell transplant should be considered. Age, overall health, and how the leukemia responds to the first round of treatment also matter a great deal. Two people in the same risk group can reasonably end up with different plans.
What it doesn't mean
A favorable-risk label is not a guarantee, and an adverse-risk label is not a fixed outcome. These are statistical patterns drawn from many past patients, applied to help plan your individual care — not a certainty about what will happen to you.
Questions to ask
- What cytogenetic and molecular results were found in my leukemia cells?
- Which risk group do these results place me in?
- How does this affect the treatment intensity being recommended?
- Is a stem cell transplant being considered because of my risk group?
- Is there a targeted therapy available for my specific mutation?
Sources
Words to know
Tap any term to see what it means.
Common questions
Why isn't AML staged like breast or colon cancer?
Staging systems for solid tumors describe how far a tumor has physically spread. AML is already in the blood and bone marrow at diagnosis, so a spread-based stage doesn't apply the same way. Instead, doctors look at the genetic makeup of the leukemia cells — their chromosome changes and gene mutations — because those features predict how the leukemia is likely to behave and respond to treatment. Many hematologists consider this more useful than a size-and-spread stage would be.
What is cytogenetics?
Cytogenetics is the study of chromosomes, the structures inside cells that carry DNA. A cytogenetic test looks at a sample of blood or bone marrow for chromosome changes, such as broken, missing, rearranged, or extra chromosomes. In AML, specific cytogenetic patterns are linked to better or worse outcomes.
What does it mean if I'm told I'm "favorable risk"?
It means the chromosome and gene changes found in your leukemia cells are, as a group, associated with better responses to standard treatment in prior studies. It is a statistical pattern, not a guarantee, and your care team will weigh it alongside your age, overall health, and how your leukemia responds to initial treatment.
What does "adverse risk" mean for my treatment?
Adverse-risk AML is more likely to be discussed alongside more intensive treatment approaches, including an earlier conversation about stem cell transplant, because these leukemias have historically been harder to control with chemotherapy alone. Ask your team exactly which adverse feature was found, since treatment options continue to evolve, including targeted therapies for specific mutations.
Can risk group change over time?
The risk group assigned at diagnosis is based on your original genetic testing. Your care team will also track how your leukemia responds to initial treatment, which is itself an important prognostic sign, alongside the ancestor risk group. Relapsed or treatment-related AML is evaluated with its own considerations.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the federal sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Last updated: 2026-08-03Next planned review: 2027-08-03
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source verified. This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source verified — This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share